GRI
Cohen & Steers Global Realty Majors ETF [GRI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GRI Stock Summary
Top 10 Correlated ETFs
GRI
Top 10 Correlated Stocks
GRI
In the News
GRI Financial details
Company Rating
-
Market Cap
1.63M
Income
-13.33M
Revenue
5.39M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.11
Forward P/E
-
PEG
0.01
P/S
-
P/B
0.65
P/C
-
P/FCF
-0.37
Quick Ratio
1.6
Current Ratio
2.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-64.31
EPS next Y
-
EPS next Q
-
EPS this Y
-96.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-14.6%
-
-
-
-
SMA20
-29.17%
SMA50
-28.17%
SMA100
8.51%
Inst Own
-
Inst Trans
-
ROA
-309%
ROE
-1164%
ROC
-5.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.503-115.5
52W High
-
52W Low
-
RSI
29.62
Rel Volume
0.56
Avg Volume
763.61K
Volume
430.52K
Perf Week
-9.52%
Perf Month
-47.69%
Perf Quarter
-25.21%
Perf Half Y
-11.36%
-
-
-
-
Beta
-1.7959
-
-
Volatility
0.04%, 0.1%
Prev Close
-17.9%
Price
0.4352
Change
-23.65%
Company Profile
- Volume Average 763.61K
- Market Capitalization 1.63M
- Employee 4
- CEO Dr. W. Marc Hertz Ph.D.
- Headquarters LA Jolla,CA,US
- IPO Date 2021-02-10
-
Website
https://www.gribio.com 
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
